Modern Psychoactive and Psychedelic Substances

Tools for Therapy and Personal Development

By Dr. Elias Rubenstein

Some experiences change more than what we see or feel. They change how we understand ourselves, other people, our memories, fears and possibilities, and our own lives. Psychoactive and psychedelic compounds can open such a window. But an intense experience does not automatically lead to clarity or change.

In Modern Psychoactive and Psychedelic Substances, Dr. Elias Rubenstein explains what matters when a compound is to be assessed for therapeutic use or personal development. Which dose allows for conversation and reflection? When does a deep, inward-directed experience unfold? Which physical and emotional reactions are part of the process? What helps in difficult moments? And how does an insight become more than a memory and turn into real change in everyday life?

The book guides the reader through the most important modern psychoactive and psychedelic compounds, from MDMA, LSD and psilocybin to DMT, mescaline and ketamine, as well as stimulants, opioids and other substances. It combines precise information with a clear eye for the human side of every experience.

A book for readers who don’t want to stop at buzzwords, fears or promises, but want to understand what these compounds can actually change, and where their limits lie.

Book cover: Modern Psychoactive and Psychedelic Substances – Tools for Therapy and Personal Development by Elias Rubenstein

Will be available soon!

Amazon Author Page Elias Rubenstein

Table of Contents

Foreword

Part I – The Psychoactive Window
1. What Makes Psychoactive Compounds Therapeutically Relevant
1.1 From Diagnosis to Therapeutic Window
1.2 Dimensions of Altered Experience
1.3 From a Temporary State to Lasting Change
1.4 Substance-Specific Windows and Applications
1.5 Therapeutic, Developmental and Insight-Oriented Use
2. The Dose Changes the Tool
2.1 Microdose
2.2 Low Dose
2.3 Full Dose/Macrodose
2.4 High Dose
2.5 Substance-Specific Terms
2.6 The Lowest Effective Dose
3. Set, Setting and Intention
3.1 The Inner Starting Point
3.2 The Environment
3.3 The Intention
3.4 Clinic, Therapeutic Space and Home
3.5 Why the Same Compound Is Experienced Differently
3.6 Compound Identity and Purity
4. The Session
4.1 Support and Communication
4.2 Difficult Experiences and When Intervention Is Needed
4.3 The End of the Effects
5. Integration
5.1 Making Sense of the Experience
5.2 Turning Insight into Behavior
5.3 Stabilizing Change in Everyday Life
6. Extraordinary States of Consciousness
6.1 Ego Dissolution, Unity and Time
6.2 Other Worlds and Entities
6.3 Spiritual and Existential Experiences

Part II – Compounds and Their Applications
7. 3,4-Methylenedioxy-N-methylamphetamine (MDMA)
7.1 Effect Profile and Therapeutic Potential
7.2 Dose, Session and Course of Effects
7.3 Supportive Measures, Medications and Risks
7.4 MDA
7.5 Methylone and Newer Entactogens
8. Lysergic Acid Diethylamide (LSD)
8.1 Effect Profile and Therapeutic Potential
8.2 Dose, Session and Course of Effects
8.3 Supportive Measures, Medications and Risks
8.4 LSD Analogues and Related Lysergamides
9. Psilocybin and Psilocin
9.1 Effect Profile and Therapeutic Potential
9.2 Dose, Session and Course of Effects
9.3 Supportive Measures, Medications and Risks
9.4 Psilocybin Analogues and Related Isolated Tryptamines
10. N,N-Dimethyltryptamine (DMT)
10.1 Effect Profile and Therapeutic Potential
10.2 Dose, Session and Course of Effects
10.3 Supportive Measures, Medications and Risks
10.4 DMT Analogues and Related Isolated Tryptamines
11. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT)
11.1 Effect Profile and Therapeutic Potential
11.2 Dose, Session and Course of Effects
11.3 Supportive Measures, Medications and Risks
11.4 5-MeO-DMT Analogues and Related 5-Methoxytryptamines
12. 2C-B
12.1 Effect Profile and Therapeutic Potential
12.2 Dose, Session and Course of Effects
12.3 Supportive Measures, Medications and Risks
12.4 2C-B Analogues and Related Phenethylamines
13. Mescaline
13.1 Effect Profile and Therapeutic Potential
13.2 Dose, Session and Course of Effects
13.3 Supportive Measures, Medications and Risks
13.4 Mescaline Analogues and Related Phenethylamines
14. Ketamine
14.1 Effect Profile and Therapeutic Potential
14.2 Dose, Session and Course of Effects
14.3 Supportive Measures, Medications and Risks
14.4 Esketamine, Arketamine and Analogues
15. Ibogaine
15.1 Effect Profile and Therapeutic Potential
15.2 Forms of Use, Dosage and Course
15.3 Physical Reactions, Risks and Interactions
15.4 Noribogaine, 18-MC, Tabernanthalog and Related Developments
16. Salvinorin A
16.1 Effect Profile and Therapeutic Potential
16.2 Dosage, Use and Therapeutic Course
16.3 Supportive Measures, Medications and Risks
16.4 Buprenorphine and μ-Opioid Windows
17. Opioids
17.1 Effect Profile and Therapeutic Potential
17.2 Dose, Session and Course of Effects
17.3 Supportive Measures, Medications and Risks
17.4 Cebranopadol, Oliceridine and New Opioid Analogues
18. Amphetamine and Other Stimulants
18.1 Effect Profile and Therapeutic Potential
18.2 Dose, Session and Course of Effects
18.3 Supportive Measures, Medications and Risks
18.4 Dextroamphetamine
18.5 Methamphetamine
18.6 Methylphenidate
18.7 Modafinil and Armodafinil
18.8 Lisdexamfetamine, Amphetamine Prodrugs and New Amphetamine Analogues
18.9 Nicotine
19. Nitrous Oxide
19.1 Effect Profile and Therapeutic Potential
19.2 Dose, Session and Course of Effects
19.3 Supportive Measures, Medications and Risks
19.4 Xenon and Related Gaseous Therapeutics
20. Non-Hallucinogenic Psychoplastogens
20.1 Effect Profile and Therapeutic Potential
20.2 Zalsupindole (DLX-001)
20.3 Neuroplasticity Without a Psychedelic Experience
20.4 Other DLX Compounds and Related Developments

Part III – Preparation, Support and Risks
21. Preparation, Therapeutic Support and Borderline Situations
21.1 The Right Time
21.2 The Feeling of Absolute Certainty
21.3 Memory and Suggestion
21.4 Self-Responsibility, Forgiveness and Inner Freedom
21.5 Information for a Medical Handover
22. Risks and Limits
22.1 Intensity Is Not the Same as Therapeutic Value
22.2 What Psychoactive Compounds Cannot Do
22.3 Self-Directed, Therapeutically Supported and Clinical Use
22.4 The Right Tool for the Right Goal
Closing Words
About Dr. Elias Rubenstein and the Hermetic Academy
More Books by the Author